Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
EXExelixis, Inc. logo

Exelixis, Inc. (EXEL)

NASDAQ Global Select · Currency in USD
$64.53 ▼ -0.78 (-1.19%)
At close: Oct 23, 4:00 PM ET. Market closed.
$64.00 ▼ -0.53 (-0.82%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$65.31
Open
$65.20
Day's Range
$63.91 – $65.20
52 Week Range
$36.00 – $65.50
Volume
2,066,169
Avg. Volume
2,474,080
Market Cap
$16.22B
Beta (5Y Monthly)
0.42
PE Ratio (TTM)
19.61
EPS (TTM)
$3.43
Earnings Date
Oct 29, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$52.33

Profile: Exelixis, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
1,077
CEO
Michael Morrissey

Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors.

Earnings

Next report: Thu, Oct 29, 2026
EPS estimate $0.89 · Revenue est. $646.51M
DateEst.Actual
Aug 5, 2026$0.85$0.91Beat
May 5, 2026$0.77$0.87Beat
Feb 10, 2026$0.77$0.94Beat
Nov 4, 2025$0.69$0.78Beat
Jul 28, 2025$0.65$0.75Beat
May 13, 2025$0.36$0.62Beat

Analyst view

Consensus price target
$52.33 ▼ -18.9%
Range $49.00 – $56.00
Rating: Hold
Buy 48% · Hold 52% · Sell 0%

Get free alerts on EXEL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.